OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results

What happened

OPKO Health reported third-quarter 2026 business highlights, including an agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp. It provides $722 million in cash at closing, subject to revenue-based adjustments, plus up to $150 million over as many as ten years tied to Labcorp sales of the 4Kscore test; approvals and closing conditions remain.

Confirmed

Global impact / market context

If completed, the BioReference sale would bring OPKO substantial cash, while the additional payment depends on Labcorp’s future 4Kscore sales. OPKO also issued $125 million in senior secured royalty notes, backed by specified royalty payments linked to its Lilly license, adding financing while directing future royalty receipts toward repayment.

Analyst inference

The update combines a planned sale of diagnostic operations with financing and an early-stage drug trial. For investors, the sale’s closing proceeds and contingent payments have different certainty, while the royalty-backed notes connect future cash receipts to financing obligations; the article gives no trial outcome or completion date.

Analyst inference

What to watch

1. Regulatory approvals and customary closing conditions must be met before the Labcorp transaction closes; the stated cash consideration may also change based on business revenues at closing. Confirmed
2. The possible additional cash payments, up to $150 million over as many as ten years, depend on Labcorp sales of OPKO’s 4Kscore test. Confirmed
3. Future royalty receipts under the Lilly license and the first-in-human OPK-8801001 trial are relevant follow-ups, but the article reports no repayment schedule or trial results. Analyst inference

Evidence

• globenewswire.com